Condition 101 About Undifferentiated Pleomorphic Sarcoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Latest Advances On Undifferentiated Pleomorphic Sarcoma

  • Condition: CD20+ B Non-Hodgkin Lymphoma
  • Journal: Zhongguo shi yan xue ye xue za zhi
  • Treatment Used: Rituximab combined with Autologous Hematopoietic Blood Stem Cell Transplantation
  • Number of Patients: 83
  • Published —
This study tested the safety and efficacy of using rituximab combined with autologous hematopoietic blood stem cell transplantation to treat patients with CD20+ B non-Hodgkin lymphoma.
  • Condition: Malignancy in Giant Cell Tumor of the Bone
  • Journal: BMC cancer
  • Treatment Used: Denosumab
  • Number of Patients: 2526
  • Published —
This study tested the safety and efficacy of using denosumab to treat patients with malignancy in giant cell tumor of the bone.

Clinical Trials For Undifferentiated Pleomorphic Sarcoma

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 63
  • Start Date: December 31, 2021
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 78
  • Start Date: March 1, 2021
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy